SBFM

EX-99.1

2 sunshine_ex9901.htm

PRESS RELEASE

Exhibit 99.1

Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year

FORT LAUDERDALE, FL / ACCESSWIRE

/ April 6, 2026 — Sunshine Biopharma Inc. (NASDAQ: SBFM) (“Sunshine Biopharma” or the “Company”), a pharmaceutical company offering and developing life-saving medicines across oncology, antivirals, and other key therapeutic areas, today announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

2025 Highlights

·Revenue of $36.3 million, representing a 4.1% increase compared to 2024.

·$2.46 million in gross proceeds raised through a registered direct offering to support expansion of sales operations.

·Nine new generic prescription drugs launched, expanding the Company’s portfolio in oncology, cardiovascular health, central nervous system disorders, and antimicrobials.

·Advancement of proprietary antiviral research, including a new series of orally active, non-covalent PLpro protease inhibitors that demonstrated dose-dependent antiviral activity in SARS-CoV-2-infected mice, strong potency in cellular models, and favorable pharmacokinetics.

Management Commentary

“We are pleased with our accomplishments in 2025, as we remain committed to reaching profitability in the near future,” said Dr. Steve Slilaty, CEO. “Looking ahead, we are excited about the opportunities for growth in 2026 and beyond as we continue expanding our generic drug portfolio and advancing our proprietary drug development programs to deliver more life-saving medicines to the market.”

Financial Summary (in millions)

2025 2024

Revenue $36.31 $34.87

Gross Profit $12.26 $10.67

General & Administrative Expenses $18.48 $16.48

Net Loss $5.98 $5.13

The increase in General & Administrative Expenses in 2025 was primarily driven by a non-cash, non-recurring impairment charge of $1.75 million related to intangible assets. Excluding this charge, the Company’s operating performance reflects a meaningful improvement over 2024.

In January 2026, Sunshine Biopharma implemented cost-reduction initiatives aimed at lowering general and administrative expenses and sharpening the Company’s focus on achieving near-term profitability. Based on current plans, these initiatives are expected to reduce expenses by approximately $2 million to $3 million in 2026, although there can be no assurance that these reductions will be fully realized.

1

About Sunshine Biopharma

Sunshine Biopharma currently markets 71 generic prescription drugs in Canada, with 12 additional launches planned for the remainder of 2026. The Company is also advancing two proprietary drug development programs:

·K1.1 mRNA, an mRNA-Lipid Nanoparticle therapeutic candidate targeting liver cancer.

·PLpro protease inhibitor, a small-molecule antiviral candidate for SARS-related coronavirus infections.

Additional information is available at www.sunshinebiopharma.com.

Forward-Looking

Statements

This press release contains forward-looking

statements based on current expectations, forecasts, and assumptions that involve risks and uncertainties. These statements include, but are not limited to, those regarding the Company’s financial performance, drug development activities, and future growth opportunities. Actual results may differ materially due to various risks and uncertainties described in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are encouraged to review the Company’s most recent SEC filings for additional information.

Contact:

Camille Sebaaly, CFO

Direct Line: 514-814-0464

camille.sebaaly@sunshinebiopharma.com

2

EX-99.1

2 sunshine_ex9901.htm

PRESS RELEASE

Exhibit 99.1

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year

FORT LAUDERDALE, FL / ACCESSWIRE / May 15, 2025 / Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2025 first quarter report on Form 10-Q on Thursday, May 15, 2025. The following are highlights of the report:

·Revenues in first quarter of 2025 were $8.9 million, up 18% over revenue of the same period last year.

·Appointed a new Chief Commercial Officer, Mr. Michel Roy, a leader in the pharma industry.

·Launched 6 new generic prescription drugs including two antibiotics, two drugs for gastrointestinal disorders and two drugs for schizophrenia.

·Completed additional studies on orthotopic human tumor models in mice further confirming the Company’s K1.1 mRNA Lipid Nanoparticle product as a novel therapeutic agent for human hepatocellular carcinoma.

"We are thrilled to report strong financial results for the first quarter of 2025, with an 18% increase in revenues compared to the same period last year. This growth reflects the continued dedication of our team, the trust of our customers, and the strength of our strategic initiatives. Sunshine Biopharma remains steadfast in its commitment to innovation, operational excellence, and delivering value to our stakeholders. As we move forward, we are focused on expanding our product pipeline, strengthening partnerships, and driving long-term sustainable growth. Our success is a testament to the resilience and ingenuity of our organization, and I am confident that we will continue to build on this momentum throughout the year," said Dr. Steve Slilaty, CEO of the Company.

The following are key elements of the Income Statement contained in the Company’s 2025 first quarter report:

2025Q1

2024Q1

Revenue $8,901,341 $7,541,046

Gross Profit $2,730,426 $2,354,337

General & Administrative Expenses $4,026,176 $3,704,926

Net Loss $1,179,771 $1,283,801

About Sunshine Biopharma Inc.

Sunshine Biopharma currently has 70 generic prescription drugs on the market in Canada and 13 additional drugs scheduled to be launched in the remainder of 2025. Among the new drugs to be launched is NIOPEG®, a biosimilar of NEULASTA®. Like NEULASTA®, NIOPEG® is a long-acting form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving anti-neoplastic therapy. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.

All registered trademarks are the property of their respective owners.

Safe Harbor Forward-Looking Statements

This press release contains forward-looking

statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the “Company”) that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company’s drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company’s filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company’s most recent SEC filings.

For more information, please contact:

Camille Sebaaly, CFO

Direct Line: 514-814-0464

camille.sebaaly@sunshinebiopharma.com

2

EX-99.1

2 sunshine_ex9901.htm

PRESS RELEASE

Exhibit 99.1

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

FORT LAUDERDALE, FL / ACCESSWIRE / April 1, 2025 / Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 annual report on Form 10-K on Tuesday, April 1, 2025. The following are highlights of the report:

·Revenue in 2024 grew to $34.9 million, a 45% increase over 2023 revenue of $24.1 million.

·Completed an underwritten public offering of approximately $10 million in gross proceeds for expansion of sales operations.

·Launched 13 new generic prescription drugs, 4 under cross-licensing agreements and 9 under distribution agreements.

·Received regulatory approval from Health Canada for marketing of the oncology drug NIOPEG®, a biosimilar of NEULASTA®.

·Announced publication of groundbreaking research results in the Journal of Medicinal Chemistry (J. Med. Chem. 2024, 67, 13681−13702) demonstrating the superior efficacy of Sunshine Biopharma’s new Coronavirus PLpro inhibitor. The study showcases a PLpro inhibitor with sub-micromolar potency and robust in vivo efficacy in a mouse model of SARS-CoV-2 infection. This peer-reviewed research marks an important milestone in Sunshine Biopharma's ongoing efforts to develop proprietary therapies in critical disease areas.

·Announced completion of mouse model studies providing proof-of-concept for the Company’s K1.1 mRNA Lipid Nanoparticle as a novel therapeutic agent for human hepatocellular carcinoma. Human hepatocellular carcinoma is the third leading cause of cancer-related deaths worldwide and the most common type of primary liver cancer in adults.

“We are pleased with our accomplishments in 2024, as we remain committed to reaching profitability in the near future,” said Dr. Steve Slilaty, CEO of the Company. “Looking ahead, we are excited about the opportunities for growth in 2025 and beyond, as we continue to advance our proprietary drug development program to deliver more life-saving medicines to the market.”

The following are key elements of the Income Statement contained in the Company’s 2024 report:

2024 2023

Revenue $34,874,283 $24,092,787

Gross Profit $10,669,794 $8,339,171

General & Administrative Expenses $16,481,915 $13,124,470

Net Loss $5,134,116 $4,506,044

1

About Sunshine Biopharma Inc.

Sunshine Biopharma currently has 70 generic prescription drugs on the market in Canada and 13 additional drugs scheduled to be launched in the remainder of 2025. Among the new drugs to be launched is NIOPEG®, a biosimilar of NEULASTA®. Like NEULASTA®, NIOPEG® is a long-acting form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving anti-neoplastic therapy. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.

All registered trademarks are the property of their respective owners.

Safe Harbor Forward-Looking Statements

This press release contains forward-looking

statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the “Company”) that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company’s drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company’s filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company’s most recent SEC filings.

For more information, please contact:

Camille Sebaaly, CFO

Direct Line: 514-814-0464

camille.sebaaly@sunshinebiopharma.com

2